IP Library Granted Patent US 7,976,854
Granted Patent B2
US 7,976,854 · App. 11/648,333 · Granted Jul 12, 2011

Method of treating skin requiring skin cancer treatment

Assignee: OMP, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,976,854
App. No.
11/648,333
Granted
Jul 12, 2011
Kind
B2
Abstract

A treatment regimen for treating skin subject to skin cancer treatments involves the application of supplemental composition(s) such as preparatory composition(s), protective composition(s), and combinations thereof, and a corrective composition.

Claims (39)

1. A method comprising:

preconditioning an area of skin of a subject by sequential topical application of a preparatory composition and a corrective composition to the area of skin; and

performing a radiation or photodynamic therapy skin cancer treatment on the preconditioned area of skin whereby preconditioning the skin reduces side effects associated with the skin cancer treatment compared to skin that is not preconditioned for receiving a skin cancer treatment.

2. A method as in claim 1 further comprising applying a protective composition after application of the corrective composition.

3. A method as in claim 1 further comprising waiting a predetermined period of time and repeating the preconditioning.

4. A method comprising:

post-treating an area of skin of a subject that has previously been treated with a radiation or photodynamic therapy skin cancer treatment by sequential topical application of a preparatory composition and a corrective composition to the area of skin whereby post-treating the skin reduces side effects associated with the skin cancer treatment compared to skin that is not post-treated after receiving a skin cancer treatment.

5. A method as in claim 4 further comprising applying a protective composition after application of the corrective composition.

6. A method as in claim 4 further comprising waiting a predetermined period of time and repeating the post-treating.

7. A method comprising:

preconditioning an area of skin of the subject by administering to the area of skin a first treatment and, after a predetermined period of time, a second treatment,

the first treatment comprising the sequential topical application of one or more preparatory compositions, a first corrective composition, and one or more protective compositions;

the second treatment comprising the sequential topical application of one or more preparatory compositions, and a second corrective composition,

wherein the second corrective composition comprises a first active ingredient sensitive to oxidation and a retinoid; and

treating the skin with a radiation or photodynamic therapy skin cancer treatment whereby preconditioning the skin reduces side effects associated with the skin cancer treatment compared to skin that is not preconditioned for receiving a skin cancer treatment.

8. The method of claim 7 wherein the one or more preparatory compositions are selected from the group consisting of cleansers, toners and combinations thereof.

9. The method of claim 7 wherein the one or more protective compositions are selected from the group consisting of sunscreens, sun blocks, moisturizers and combinations thereof.

10. The method of claim 7 wherein the first corrective composition comprises an active ingredient that is sensitive to oxidation; a preservative; a chelating agent; an emulsifier; a humectant; a pH adjuster; an antioxidant; an emollient; a reducing agent and water.

11. The method of claim 7 wherein the first corrective composition comprises hydroquinone.

12. The method of claim 7 wherein the second corrective composition further comprises a preservative; a chelating agent; an emulsifier; a humectant; a pH adjuster; an antioxidant; an emollient; a reducing agent and water.

13. The method of claim 7 wherein the first active ingredient is hydroquinone.

14. The method of claim 7 further comprising the step of waiting at least four hours between the first treatment and the second treatment.

15. The method of claim 7 further comprising

post-treating the skin of the subject treated with a radiation or photodynamic skin cancer treatment by administering to the area of skin a first treatment and, after a predetermined period of time, a second treatment,

the first treatment comprising the sequential topical application of one or more preparatory compositions, a first corrective composition, and one or more protective compositions;

the second treatment comprising the sequential topical application of one or more preparatory compositions, and a second corrective composition,

wherein the second corrective composition comprises a first active ingredient sensitive to oxidation and tretinoin.

16. A method comprising:

preconditioning an area of skin of the subject by administering to the area of skin a first treatment and, after a predetermined period of time, a second treatment,

the first treatment comprising the sequential topical application of a cleanser, a toner, a first corrective composition containing hydroquinone, and a protective composition;

the second treatment comprising the sequential topical application of a cleanser, a toner, a second corrective composition comprising hydroquinone and a retinoid; and

performing a radiation or photodynamic therapy skin cancer treatment on the preconditioned area of skin whereby preconditioning the skin reduces side effects associated with the skin cancer treatment compared to skin that is not preconditioned for receiving a skin cancer treatment.

17. The method of claim 16 further comprising post-treating the area of skin subjected to the skin cancer treatment by administering to the area of skin a first treatment and, after a predetermined period of time, a second treatment,

the first treatment comprising sequential topical application of a cleanser, a toner, a first corrective composition containing hydroquinone, and a protective composition;

the second treatment comprising sequential topical application of a cleanser, a toner, a second corrective composition comprising hydroquinone and a retinoid.

18. The method of claim 16 wherein the first pre-conditioning treatment occurs in the morning.

19. The method of claim 18 wherein second pre-conditioning treatment occurs at least four hours after the first pre-conditioning treatment.

20. The method of claim 17 wherein the first post-treating treatment occurs in the morning.

21. The method of claim 20 wherein second post-treating treatment occurs at least four hours after the first post-treating treatment.

Assignments (20)
SECURITY INTEREST Recorded Jul 30, 2026
From: OBAGI COSMECEUTICALS LLC
To: MIDCAP FINANCIAL TRUST, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
Reel/Frame 075464/0639 →
RELEASE OF SECURITY INTEREST Recorded Nov 17, 2025
From: TCW ASSET MANAGEMENT COMPANY LLC, AS ADMINISTRATIVE AGENT
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 072928/0385 →
PATENT SECURITY AGREEMENT Recorded Nov 17, 2025
From: OBAGI COSMECEUTICALS LLC
To: LSSF II OFFSHORE INVESTMENTS, LP, AS ADMINISTRATIVE AGENT
Reel/Frame 073625/0459 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
RELEASE OF SECURITY INTEREST Recorded Mar 21, 2025
From: JPMORGAN CHASE BANK, N.A.
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 070592/0979 →
SECURITY INTEREST Recorded Mar 18, 2025
From: OBAGI COSMECEUTICALS LLC
To: TCW ASSET MANAGEMENT COMPANY LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 070546/0595 →
SECURITY INTEREST Recorded Aug 1, 2022
From: OBAGI COSMECEUTICALS LLC
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 060690/0148 →
RELEASE OF SECURITY INTEREST Recorded Jul 29, 2022
From: TCW ASSET MANAGEMENT COMPANY LLC
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 060668/0771 →
RELEASE OF SECURITY INTEREST Recorded Mar 19, 2021
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 055652/0735 →
SECURITY INTEREST Recorded Mar 16, 2021
From: OBAGI COSMECEUTICALS LLC
To: TCW ASSET MANAGEMENT COMPANY LLC, AS COLLATERAL AGENT
Reel/Frame 055613/0083 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Dec 13, 2018
From: OBAGI COSMECEUTICALS LLC
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 047873/0114 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 11, 2017
From: OMP, INC.
To: OBAGI COSMECEUTICALS LLC
Reel/Frame 044829/0244 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Nov 14, 2017
From: BANK OF NEW YORK MELLON
To: OMP, INC.
Reel/Frame 044765/0176 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Nov 14, 2017
From: BARCLAYS BANK PLC
To: OMP, INC.
Reel/Frame 044440/0037 →
SECURITY INTEREST Recorded Jul 19, 2017
From: OMP, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043041/0751 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2017
From: HATTENDORF, JUDY; CARLSON, STEVE
To: OMP, INC.
Reel/Frame 042344/0564 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Jul 29, 2013
From: OMP, INC.
To: GOLDMAN SACHS LENDING PARTNERS LLC
Reel/Frame 030919/0031 →
RELEASE OF SECURITY INTEREST Recorded May 30, 2013
From: COMERICA BANK, A TEXAS BANKING ASSOCIATION, AS AGENT
To: OBAGI MEDICAL PRODUCTS, INC.; OMP, INC.
Reel/Frame 030518/0552 →
SECURITY AGREEMENT Recorded Jan 5, 2009
From: OMP, INC.; OBAGI MEDICAL PRODUCTS, INC.
To: COMERICA BANK, AS AGENT
Reel/Frame 022052/0174 →
Continuity (2)
Provisional Application 60755359 · Dec 30, 2005
Related Publication 20070154503A1 · Jul 5, 2007